Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, et al. Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5(6):628–39.

PubMed  Google Scholar 

Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104.

CAS  PubMed  Google Scholar 

Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404–23.

PubMed  Google Scholar 

Liu X, Nie L, Zhang Y, Yan Y, Wang C, Colic M, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol. 2023;25:404–14.

CAS  PubMed  PubMed Central  Google Scholar 

Zheng P, Zhou C, Ding Y, Duan S. Disulfidptosis: a new target for metabolic cancer therapy. J Exp Clin Cancer Res. 2023;42(1):103.

PubMed  PubMed Central  Google Scholar 

Jiang W, Pan S, Chen X, Wang ZW, Zhu X. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy. Mol Cancer. 2021;20(1):116.

CAS  PubMed  PubMed Central  Google Scholar 

Yao ZT, Yang YM, Sun MM, He Y, Liao L, Chen KS, et al. New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer. Cancer Commun. 2022;42(2):117–40.

Google Scholar 

Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66(2):253–62.

PubMed  Google Scholar 

Chen C, Zheng H, Luo Y, Kong Y, An M, Li Y, et al. SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer. J Clin Invest. 2021. https://doi.org/10.1172/JCI146431.

Article  PubMed  PubMed Central  Google Scholar 

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-56.e25.

CAS  PubMed  PubMed Central  Google Scholar 

Tao Y, Chen Q, Zhao C, Yang X, Cun Q, Yang W, et al. The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1. Int J Med Sci. 2020;17(6):734–44.

CAS  PubMed  PubMed Central  Google Scholar 

Zhao D, Zhao H, He Y, Yang Y, Du Y, Zhang M. The inhibitive effects of proteasome inhibitor MG-132 on pterygium fibroblasts in vitro and the potential key regulators involved. Life Sci. 2021;270: 119088.

CAS  PubMed  Google Scholar 

He T, Yuan C, Zhao C. Long intragenic non-coding RNA p53-induced transcript (LINC-PINT) as a novel prognosis indicator and therapeutic target in cancer. Biomed Pharmacother. 2021;143: 112127.

CAS  PubMed  Google Scholar 

Wang YH, Guo Z, An L, Zhou Y, Xu H, Xiong J, et al. LINC-PINT impedes DNA repair and enhances radiotherapeutic response by targeting DNA-PKcs in nasopharyngeal cancer. Cell Death Dis. 2021;12(5):454.

CAS  PubMed  PubMed Central  Google Scholar 

Jia M, Li Z, Pan M, Tao M, Wang J, Lu X. LINC-PINT suppresses the aggressiveness of thyroid cancer by downregulating miR-767-5p to induce TET2 expression. Mol Ther Nucleic Acids. 2020;22:319–28.

CAS  PubMed  PubMed Central  Google Scholar 

Han X, Liu J, Liu Y, Mou L, Li C. LINC-PINT inhibited malignant progression of bladder cancer by targeting miR-155-5p. Cancer Manag Res. 2021;13:4393–401.

CAS  PubMed  PubMed Central  Google Scholar 

Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med. 2022;28(2):345–52.

CAS  PubMed  PubMed Central  Google Scholar 

Sušac L, Vuong MT, Thomas C, von Bülow S, O’Brien-Ball C, Santos AM, et al. Structure of a fully assembled tumor-specific T cell receptor ligated by pMHC. Cell. 2022;185(17):3201-13.e19.

PubMed  PubMed Central  Google Scholar 

Labanieh L, Majzner RG, Klysz D, Sotillo E, Fisher CJ, Vilches-Moure JG, et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell. 2022;185(10):1745-63.e22.

CAS  PubMed  PubMed Central  Google Scholar 

Zhou Q, Chen S, Lu M, Luo Y, Wang G, Xiao Y, et al. EFEMP2 suppresses epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in human bladder cancer. Int J Biol Sci. 2019;15(10):2139–55.

CAS  PubMed  PubMed Central  Google Scholar 

Yoshida GJ. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. J Exp Clin Cancer Res. 2020;39(1):112.

CAS  PubMed  PubMed Central  Google Scholar 

Avery L, Filderman J, Szymczak-Workman AL, Kane LP. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. Proc Natl Acad Sci USA. 2018;115(10):2455–60.

CAS  PubMed  PubMed Central  Google Scholar 

Correnti CE, Laszlo GS, de Van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia. 2018;32(5):1239–43.

CAS  PubMed  PubMed Central  Google Scholar 

Gao S, Hsu TW, Li MO. Immunity beyond cancer cells: perspective from tumor tissue. Trends Cancer. 2021;7(11):1010–9.

CAS  PubMed  PubMed Central  Google Scholar 

Li G, Kryczek I, Nam J, Li X, Li S, Li J, et al. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol. 2021;23(5):526–37.

CAS  PubMed  PubMed Central  Google Scholar 

Jiang M, Zhang S, Yang Z, Lin H, Zhu J, Liu L, et al. Self-RECOGNITION OF AN INDUCIBLE HOST lncRNA by RIG-I feedback restricts innate immune response. Cell. 2018;173(4):906-19.e13.

CAS  PubMed  Google Scholar 

Park EG, Pyo SJ, Cui Y, Yoon SH, Nam JW. Tumor immune microenvironment lncRNAs. Brief Bioinform. 2022;23(1):bbab504.

PubMed  Google Scholar 

Rey-Cárdenas M, Guerrero-Ramos F, Gómez de Liaño Lista A, Carretero-González A, Bote H, Herrera-Juárez M, et al. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. Cancer Treat Rev. 2021;93:102142.

PubMed  Google Scholar 

Iacovelli R, Ciccarese C, Brunelli M, Battelli N, Buttigliero C, Caserta C, et al. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin. Ann Oncol. 2022;33(11):1179–85.

CAS  PubMed  Google Scholar 

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.

PubMed  PubMed Central  Google Scholar 

Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov. 2022;21(4):261–82.

CAS  PubMed  PubMed Central  Google Scholar 

Yamamoto TN, Kishton RJ, Restifo NP. Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat Med. 2019;25(10):1488–99.

CAS  PubMed  Google Scholar 

Hollern DP, Xu N, Thennavan A, Glodowski C, Garcia-Recio S, Mott KR, et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell. 2019;179(5):1191-206.e21.

CAS  PubMed  PubMed Central  Google Scholar 

Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nat Med. 2023;29(2):440–9.

CAS  PubMed  PubMed Central  Google Scholar 

Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8(8):1160–8.

PubMed  PubMed Central